Comparison of molecular assays for HPV testing in oropharyngeal squamous cell carcinomas: a population-based study in Northern Ireland


Published in:
Cancer Epidemiology, Biomarkers, & Prevention

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2019 American Association for Cancer Research. This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Title: Comparison of molecular assays for HPV testing in oropharyngeal squamous cell carcinomas: a population-based study in Northern Ireland

Authors and affiliations: Stephanie G. Craig¹,², Lesley A. Anderson³,⁴, Michael Moran⁵, Laura Graham¹,², Keith Currie¹,², Keith Rooney⁶, Max Robinson⁷, Victoria Bingham¹,², Kate S. Cuschieri⁸, Stephen McQuaid¹,²,¹¹, Andrew G. Schache⁹, Terry M. Jones⁹, Dennis McCance¹⁰, Manuel Salto-Tellez¹,²,¹¹, Simon S. McDade’, Jacqueline A. James¹,²,¹¹.

1. Northern Ireland Molecular Pathology Laboratory, Queen’s University Belfast, Belfast, Northern Ireland, UK
2. Centre for Cell Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, UK
3. Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK
4. Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK
5. Pfizer Pharma GmbH, Berlin, Germany
6. Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK
7. Centre for Oral Health Research, Newcastle University, England, UK
8. National Health Service Lothian, Edinburgh, Scotland, UK
9. Liverpool Head & Neck Centre, Institute of Translational Medicine, University of Liverpool, England, UK
10. Department of Pathology and the University of New Mexico Comprehensive Cancer Centre, University of New Mexico Medical School, Albuquerque, NM 87131, USA
11. Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK

Correspondence to: Dr Jacqueline James, Northern Ireland Molecular Pathology Laboratory, Centre for Cell Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, UK, BT9 7AE; Telephone +44(0)28 9097 5781; Email j.james@qub.ac.uk

Running title: Comparison of Molecular Assays for HPV Testing

Keywords: OPSCC; Molecular Stratification; HPV; p16 IHC; HPV ISH

Conflict of interest: Dr. Moran is an employee of Pfizer Pharma GmbH; Dr. Robinson has consultancy with Leica Biosystems Ltd. These activities have no relationship with the submitted publication. All other authors declare no competing interests.

Funding: The funders had no role in study design, collection, data analysis or interpretation of the data. This work received funding from the Medical Research Council (R1310CNR; DMcC and JJ), the Health and Social Care Research and Development Division of the Northern Ireland Public Health Agency (R4556CNR; DMcC, JJ, MMo), Cancer Research UK (R2111CNR; MST and JJ), the Wellcome Trust (WT093893MA; AS) and GlaxoSmithKline Ltd (TJ). The Northern Ireland OPSCC TMAs used in this research were received from the Northern Ireland Biobank which has received funds from Health and Social Care Research and Development Division of the Public Health Agency in Northern Ireland and the Friends of the Cancer Centre. The Northern Ireland Cancer Registry who receives funding from the Northern Ireland Public Health Agency carried out collection of clinical data for the Northern Ireland OPSCC patients.

Word Count (Abstract): 249 words
Word Count (Manuscript): 3657 words
Number of Figures: 4
Number of Tables: 2
Supplementary Material: 4
Abstract

Background
Determination of HPV status has become clinically relevant for patient stratification under UICC TNM8 staging. Within the UK, a combination of p16 IHC and HPV DNA-ISh is recommended for classifying HPV status. This study will assess a series of clinically applicable second-line molecular tests to run in combination with p16 IHC to optimally determine HPV status.

Methods
The ability of HPV RNA-ISh, HPV DNA-ISh and HPV DNA-PCR to identify p16-positive/HPV-positive patients was investigated in a population-based OPSCC cohort of patients diagnosed in Northern Ireland from 2000-2011.

Results
Only 41% of the Northern Irish OPSCC patient population was associated with HPV-driven carcinogenesis. Both ISh assays were more specific than the DNA-PCR assay (100% and 95% vs 67%) and were less likely to be affected by pre-analytical factors such as increasing block age. A pooled HPV genotype probe for RNA-ISh was found to be the most accurate molecular assay assessed (95% accuracy) when compared to p16 positivity.

Conclusions
Our study demonstrates the advantage of tissue-based molecular assays when determining HPV status in retrospective samples. Specifically, we demonstrate the enhanced sensitivity and specificity of ISh techniques compared to PCR based methodology when working with FFPE tissue and found HPV RNA-ISh to be the most effective assay for determining HPV status.

Impact
As p16 IHC is a relatively inexpensive, accessible and sensitive test for stratifying patients by HPV status, this study finds more patients would benefit from first-line p16 IHC followed by specific HPV testing using HPV RNA-ISh to confirm HPV status.
**Introduction**

Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) are distinct to HPV-negative OPSCC.¹ Patients presenting with HPV-related OPSCC tend to be younger, non-smokers, non-drinkers and to have fewer co-morbidities compared to their HPV-negative counterparts.² Clinical trials comparing HPV-related and HPV-negative OPSCC have conclusively demonstrated that patients with HPV-related OPSCC have better prognosis.³ Subsequently, molecular stratification of patients with OPSCC based on HPV status has been considered for the clinical management of OPSCC following early results from clinical trials.⁴ Most recently, the eighth edition of the American Joint Committee on Cancer and the Union for International Cancer Control TNM staging guidelines have adjusted the staging criteria for HPV-related OPSCC, down-staging them.⁵,⁶ Underpinning the new staging criteria and the advances in the clinical management of OPSCC is how HPV status is determined. The most recent guidelines produced by the College of American Pathologists detail that p16 IHC testing alone is sufficient for the molecular stratification of OPSCC.¹ However, in the UK, the Royal College of Pathologists still promote use of HPV DNA-ISH in combination with p16 IHC to determine HPV status.⁷,⁸

The aim of this study was to compare different types of molecular HPV tests against p16 IHC as a second line-test in a large, population-based UK cohort of OPSCC patients. Three HPV tests suitable for clinical HPV testing on FFPE were compared to p16 IHC as a single test and as a second-line test, with their effect on patient outcome evaluated by survival analyses and relationship to p16 positivity. This study will address which molecular assay is optimal for second-line HPV testing following p16 IHC in OPSCC.
Materials and Methods

Patients

The study was conducted according to the Good Clinical Practice guidelines and the Declaration of Helsinki. OPSCCs diagnosed in Northern Ireland from 2000 to 2011 were identified within the Belfast Health and Social Care Trust under ethical approval from the Northern Ireland Biobank (OREC 16/NI/0030; NIB 11/0001). Patients identified in this study were considered representative of all OPSCC patients in Northern Ireland during the study period. Inclusion criteria were based on confirmed diagnosis of an untreated primary OPSCC; here defined as either base of tongue (C01), soft palate (C05.1), uvula (C05.2) tonsils (C09), or oropharynx not otherwise specified (C10.9).

Clinical data were retrieved from individual patient electronic clinical records through the Northern Ireland Cancer Registry. Data recorded for each cohort included sex, age, TNM7 stage, treatment received, smoking history, alcohol history, date of diagnosis and death. Overall survival was defined as the time from diagnosis until time of death as recorded on the death certificate. Data were right censored for patients still alive until the study censor date (12/05/2016).

Procedures

Using patient FFPE material arrayed on tissue microarrays (TMAs) all patients were assessed for p16 IHC as previously described using a Ventana Benchmark Autostainer with a commercial kit (CINtec® p16 Histology; Roche, Tuscon AZ, USA; catalog number: 725-4713) at the Newcastle upon Tyne Hospitals NHS Foundation Trust.9 For each patient, triplicate TMA cores were independently assessed by two investigators for all assays. Patients were considered p16-positive by p16 IHC if there was strong, diffuse staining in at
least 70% of tumor cells.\textsuperscript{10} Digital image analysis using QuPath was applied to confirm average expression of p16 IHC in the tumour cells.\textsuperscript{11}

HPV RNA-ISH was carried out on all TMAs and scored only for cores for which suitable mRNA integrity had been detected with positive (\textit{PPIB}) and negative (\textit{DapB}) reagent controls (Advanced Cell Diagnostics; Newark, CA, USA; catalog numbers: 313901 for \textit{PPIB} and 310043 for \textit{DapB}).\textsuperscript{12} Patient FFPE material positive by \textit{PPIB} but negative for \textit{DapB} were considered suitable for analysis by the test probe for HPV. High-risk HPV RNA-ISH was undertaken using RNAscope 2.0 manual assay with a pooled HPV genotype detection kit (Probe-HPV-HR18 recognising HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 E6/E7 mRNA, Advanced Cell Diagnostics, catalog number: 312591) within the Northern Ireland Molecular Pathology Laboratory. Patients were considered HPV RNA-ISH positive if the tumor tissue demonstrated punctate dots of brown reaction product specifically localising within the malignant cells.\textsuperscript{13}

High-risk HPV DNA-ISH was conducted on TMAs as previously described using a Ventana Benchmark Autostainer with a commercial kit (Inform HPV III family 16 probe (B) recognising HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 subtypes, Roche, catalog number: 800-4295) at the Newcastle upon Tyne Hospitals NHS Foundation Trust.\textsuperscript{9} Patients were considered positive for HPV DNA-ISH if tumor tissue demonstrated blue reaction product specifically localising within the malignant nuclei.\textsuperscript{14}

HPV DNA-PCR was undertaken as previously described using a commercially available qualitative PCR-based assay specialised for generalised HPV genotyping (Optiplex HPV Genotyping Kit recognising HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53,
56, 58, 59, 66, 68, 70, 73 and 82 types, DiaMex; Heidelberg, Germany; catalog number: IN0601) at the Scottish HPV Reference Laboratory.\textsuperscript{15} HPV-positive Caski cells and water acted as positive and negative controls respectively for the test and were run in parallel. Cross contamination, resulting from sectioning was checked on sections taken from a virgin wax FFPE block containing no sample. Reagent blanks from the DNA extraction process were also checked for cross contamination. For patient genotyping, each sample underwent PCR amplification using primers designed for independent, co-amplification of 24 high-risk HPV genotypes and the human \( \beta \) globin gene which acted as an internal control for sample adequacy. Patients were considered HPV-positive if they were genotyped for a specific HPV type and if there was adequate human \( \beta \) globin gene expression. Patients with negative genotyping results with positive human \( \beta \) globin gene expression were considered HPV-negative.

**Statistical Analysis**

Cohort baseline characteristics were compared between patients for known/unknown HPV status and p16 status using Pearson’s chi-square test for independence. The gold standard for HPV testing in other cancers types uses a PCR-based test on fresh frozen tissue in order to determine HPV status of the patient.\textsuperscript{16} The Royal College of Pathologists and the College of American Pathologists recognise a lack of fresh frozen material collected in OPSCC for HPV testing and have produced guidelines for what should be done to determine HPV status in patients with OPSCC. Both recommend use of p16 immunohistochemistry (IHC), a highly sensitive if somewhat non-specific biomarker, to identify patients that may have HPV-related OPSCC.\textsuperscript{1,7,8} Therefore, determination of sensitivity and specificity of HPV DNA-ISH, HPV RNA-ISH and HPV DNA-PCR was carried out against p16-positive patients which is likely to become the clinical gold standard for these patients.\textsuperscript{17} Time trend analysis was conducted
using logistic regression of p16-negative/HPV-positive and p16-positive/HPV-negative patients against incidence before and after 2006. The Welch two sample t test was used to determine difference in p16 expression against p16/HPV status.

Overall five-year survival analysis using the Kaplan-Meier method was conducted. Survival curves were compared using the log-rank test. The missing indicator method was used to handle missing clinical data. Cox proportional-hazards models were used to calculate hazard ratios (HR) and associated 95% confidence intervals (CI). Multivariable models were developed by backwards selection of age, sex, smoking status, alcohol history, treatment, block age and TNM7 staging.

The reporting standards of the study fulfil recommendations set by the STROBE statement for reporting of observational studies and REMARK guidelines for tumor biomarker prognostic studies.18,19

**Results**

**Clinical Cohort**

From 2000 to 2011, 337 patients with OPSCC were identified in Northern Ireland, Figure 1. Following case note review, 43 patients were excluded leaving 294 (100%) patients in the overall cohort. Of these, 250 (85%) patients had biopsy or resection specimens’ available for HPV testing. HPV status was determined by p16 IHC, HPV genotyping, high-risk HPV DNA-ISH and RNA-ISH in 221 (75%) patients. The 221 OPSCC cases analysed in this study are considered to be representative of all OPSCC patient’s in Northern Ireland in terms of TNM7 stage, treatment received and proportion of deaths that occurred, Table 1.
Of the 221 patients assessed in this study, 90 (41%) were p16-positive. Mean follow-up time was 3.2 years (Range 0.02-10.00 years). p16-positive OPSCC was more common in patients under 60 years of age, those who were non-smokers, those presenting with advanced stage according to TNM7 and to have received primary surgery with curative intent (p < 0.0048), Table 2.

**Comparison of HPV molecular testing to p16 IHC**

HPV DNA-ISH identified the least number of HPV-positive cases (n=67), whilst HPV DNA genotyping identified the most (n=114). All cases considered positive by either HPV DNA-ISH or HPV RNA-ISH were found to be HPV-positive by p16 IHC. Moreover, all cases positive by HPV DNA-ISH, were also positive by HPV RNA-ISH resulting in a distinctive staining pattern amongst the three tests for each patient, Figure 2. Of all of the p16-positive cases, only ten were negative by both ISH techniques. If HPV DNA-ISH had been used alone more than double the number of p16-positive/HPV-negative patients (n=23) would have been identified. In contrast, a significant proportion of HPV DNA genotyping positive patients were not HPV-positive by p16 IHC, DNA-ISH or RNA-ISH (38%). Of interest, HPV DNA genotyping was the only molecular HPV assay to identify p16-negative/HPV-positive cases, Figure 3A. Using digital image analysis no significant difference was observed for p16 IHC expression between patients who were p16-positive/HPV-negative or p16-positive/HPV-positive (p = 0.1002 and p = 0.0672 for HPV RNA-ISH and HPV DNA-PCR respectively), Supplementary Figure S1A and S1B. However, patients who were HPV-positive by HPV DNA-PCR and who were classified as p16-negative based on p16 IHC expression (i.e. have less than 70% positive staining present in tumour epithelium) were more likely to demonstrate even lower levels of p16 IHC expression than patients who were p16-negative/HPV-negative by HPV DNA-PCR (p=0.0404), Supplementary Figure S1B.
p16 IHC is a highly sensitive surrogate biomarker used to predict HPV-status in FFPE tissue, therefore, the ability of the three molecular assays for appropriate HPV detection was carried out against p16 status. All three tests demonstrated comparable sensitivity for the detection of HPV in p16-positive cases (89%, 95% CI: 81-95%, for HPV RNA-ISH; 79%, 95% CI: 69-87%, for HPV DNA-PCR and 74%, 95% CI: 64-83%, for HPV DNA-ISH), Figure 3B. Specificity for both ISH techniques was superior to PCR-based HPV detection (100%, 95% CI: 87-100%, for HPV RNA- and DNA-ISH vs 67%, 95% CI: 58-75% for HPV DNA-PCR), Figure 3C. Out of the three tests, the most accurate was HPV RNA-ISH with the ability to detect HPV RNA in 95% (95% CI: 92-98%) of p16-positive cases, followed by HPV DNA-ISH with 90% (95% CI: 85-93%) and HPV DNA-PCR with 72% (95% CI: 66-78%) detection.

Within the Northern Ireland cohort incidence of p16-negative/HPV-positive OPSCC was limited to a singular molecular assay; HPV DNA-PCR. Incidence of these p16-negative/HPV-positive cases was found to decrease with decreasing age of the block in patient samples taken before 2006 (p = 0.1530), Figure 3D. In contrast, p16-positive/HPV-negative cases were seen with similar incidence in all three molecular assays independent of FFPE block year (p = 0.0131), Figure 3E.

**Prevalence of the HPV-16 Genotype vs other Genotypes driving HPV-related OPSCC**

HPV DNA-PCR determined that HPV-positive patients in the cohort arose from only HPV-16 (n=110), HPV-18 (n=1) and HPV-33 (n=3; 2 of which co-expressed HPV-16 DNA) genotypes, with 98% of HPV DNA genotyping positive cases containing HPV-16 DNA. Of the non-HPV-16 genotypes, only one was not p16-positive (HPV-33). Parallel to HPV DNA-
PCR, HPV status using high-risk HPV RNA-ISH was assessed independently using a single probe targeting HPV-16 only and also a high-risk cocktail probe targeting 18 genotypes. Of the HPV-positive cases assessed by HPV RNA-ISH (single probe only), 93% contained HPV-16 RNA which concurs with HPV DNA genotyping. Results from both HPV RNA-ISH probe sets were concordant except in six cases were the single probe was negative and the cocktail probe positive. Of these, according to HPV DNA-PCR, all p16-positive, non-HPV-16 DNA cases were identified (n=3). The other three cases, which contained HPV-16 DNA according to genotyping, were positive by the cocktail probe alone.

**Stratification of patient prognosis by HPV molecular testing vs p16 IHC**

Determining ‘HPV’ status was found to have comparable survival for p16 IHC (HR 0.31 [95% CI: 0.20-0.48]), HPV RNA-ISH (HR 0.26 [95% CI: 0.16-0.42]) and HPV DNA ISH (HR 0.23 [95% CI: 0.13-0.40]), but not HPV DNA-PCR (HR 0.67 [95% CI: 0.47-0.97]), Figure 4A, 4B, 4C, 4D. Comparable hazard ratios were observed following adjustment for age, sex, TNM7 stage, smoking, alcohol history, block age and treatment received indicating similar survival predictions in the adjusted models, Supplementary Table S1. Results for p16 IHC (our gold standard) were not found to vary with respect to covariate strata or missing clinicopathological data, Supplementary Figure S2 and Supplementary Table S2. Combination of p16 IHC positive and HPV DNA-PCR positive patients to determine HPV status improved stratification of patients for survival predictions using HPV DNA-PCR (HR 0.33 [95% CI: 0.21-0.54]), Figure 4E. Combination of results for p16 IHC and HPV RNA-ISH (the most accurate HPV molecular assay assessed) demonstrated significant five-year survival overall and identified a group of patients who were p16-positive/HPV-negative (Log Rank p < 0.0001), Figure 4F. Interestingly, the mortality of p16-positive/HPV-negative patients alive after five years (30%) was found to be similar to p16-negative/HPV-negative
patients (33%) (HR 0.87 [95% CI: 0.40-1.87]) and this relationship is maintained when adjusted for clinicopathological covariates, Supplementary Table S1. Patients who were p16-negative/HPV-positive by HPV DNA-PCR were not found to have significantly different survival outcomes to p16-negative/p16-positive patients (HR 1.25 [95% CI: 0.81-1.95]), Supplementary Figure S1C.

Discussion

Due to its sensitivity, low cost, easy implementation and simple interpretation for pathologists p16 IHC has dominated over any other test to gauge HPV status in OPSCC. The main aim of the present study was to identify an appropriate second-line test for confirming HPV status in p16-positive OPSCC.

The results of the present study demonstrate that only 89% of cases positive for p16 were found to transcribe high-risk HPV E6 and E7 mRNA within a clinically and pathologically well-defined OPSCC cohort. Such findings are similar to those reported by Morbini et al., 2015 who also found concomitant expression of HPV in 90% of the p16-positive cases identified in the study when using the RNAscope® assay. These findings are also supported by Upile et al., 2014 who proposed that p16 overexpression and HPV-mediated carcinogenesis within the oropharynx are often analogous and showed in their cohort that 91% of p16-positive cases were also HPV-positive by their three-tier algorithm which utilised p16 IHC, HPV DNA ISH and qPCR. A limitation of the findings of Upile et al., 2014, however, is that their use of qPCR confirmation is limited to the HPV-16 genotype. In our study, HPV DNA-PCR was found to be the worst predictor of p16 positivity. This result was not unexpected and is in agreement with Perrone et al 2011 who recognised that qualitative PCR based tests are more prone to false positive HPV detection than ISH due to an inability
to distinguish between driver and passenger DNA in the samples.\textsuperscript{23} In contrast, ISH approaches are less likely to detect HPV DNA or RNA as a consequence of non-causal HPV or deposition arising from long term storage and may explain why temporal changes between ISH and p16 IHC were not observed in the current study.\textsuperscript{12} A limitation of this study is the possibility of p16-positive/HPV-negative cases arising due to a sampling error from using TMAs for assessment. However, our results are in line with the 10-20\% widely cited in the literature, despite the relatively small cohort size and use of TMA assessment therefore demonstrating the lack of p16 specificity for HPV detection in OPSCC.\textsuperscript{2,10,14,21,24-28}

Moreover, we demonstrate that expression of p16 IHC in patients who were p16-positive/HPV-negative is not significantly different to patients who are p16-positive/HPV-positive using digital image analysis, a finding supported in other studies who have assessed p16 expression outside of the oropharynx.\textsuperscript{29}

Based on the published literature there is still some confusion whether there is a long-term difference with respect to prognosis between cases that are p16-positive/HPV-negative and those that are p16-positive/HPV-positive i.e. true HPV mediated OPSCC. There is emerging evidence that p16 IHC alone is not sufficient for stratifying patients by HPV status.\textsuperscript{17,30} Unfortunately, differences regarding how subgroups were defined or selected have made interpretations of existing literature difficult; additionally variabilities in assay utilisation and a lack of strict site specification within the cohorts have also created confounding results.\textsuperscript{31} Differences in site can lead to discrepancies in agreement between studies as outside of the oropharynx co-expression of HPV and p16 overexpression is uncommon.\textsuperscript{10,29} Furthermore, recent studies have seen the introduction of HPV RNA-ISH included to assess HPV status.\textsuperscript{13,21,28} These articles recognise the limitations of using currently available tests for HPV detection in isolation and recognise that for clinical utility diagnostic algorithms
implementing a multi-test strategy is required to overcome the limitations of the single assays. A strength of the present study is that all the direct comparison HPV detection assays analysed (HPV RNA-ISH, HPV DNA-ISH and HPV DNA-PCR) possessed an overlapping range of comparable genotypes; both the HPV RNA-ISH and HPV DNA-PCR could detect all twelve of the genotypes detected by HPV DNA-ISH. This meant that through the design of this investigation appropriate comparisons regarding the sensitivity and specificity of each direct HPV detection assay could be made with respect to p16 positivity. Moreover, the prevalence of high-risk genotypes in Northern Ireland was also assessed using two methods, HPV RNA-ISH and HPV DNA-PCR. HPV-16 was found to be the most frequent driver of HPV-mediated carcinogenesis in the population by both tests, a finding supported in the literature. In the current investigation, our findings strongly agree with both those published by Rietbergen et al., 2013 as this work presented in this study has demonstrated that p16 in the absence of HPV does not lead to improved survival for patients with OPSCC. This is in contrast to the College of American Pathologists guidelines, which state that there is inadequate evidence to support use of a second line test such as DNA-ISH, which is known to lack sensitivity. This study shows that p16-positive/HPV-negative patients have a prognosis that is similar to p16-negative individuals and so emphasizes the importance of HPV testing after p16 triage.

Another key consideration for standardised HPV testing are ongoing clinical trials, which use HPV DNA-ISH rather than RNA-ISH as a patient selection criteria. In the present study an additional 13 cases were identified as HPV-positive by HPV RNA-ISH. Whilst both HPV DNA-ISH and RNA-ISH were found to be comparable in terms of accuracy, this study demonstrated a 14.45% increase in the number of cases considered HPV positive by HPV RNA-ISH. This finding which concurs with Morbini (a) et al., 2015 who found a 10%
difference in the cases identified as positive by both p16 and HPV DNA-ISH or HPV RNA-ISH.\textsuperscript{21} Based on this study it is possible that phase III clinical trials in OPSCC, which use DNA-ISH rather than RNA-ISH may be under recruiting patients who could have benefited from reduced treatment.\textsuperscript{33} Knowing which Molecular HPV assay will be applied, if any, is critical as the current study demonstrates differences in specificity between the available techniques.

In conclusion, p16 IHC was found to be a very sensitive biomarker as a surrogate for ‘HPV status’ and in addition was an excellent choice for a first line clinical test due to its low cost, ease of interpretation and its capacity to be easily integrated into diagnostic molecular pathology laboratories. Of the three direct HPV detection assays, the two tissue-based assays HPV DNA-ISH and RNA-ISH were found to be equally accurate with respect to p16 overexpression. Both tests demonstrate similar clinical utility as a first line test comparable to p16 positivity. Both p16 IHC and HPV DNA ISH are already in place within the diagnostic setting, use of the RNAscope\textregistered assay would have additional cost implications for undertaking clinical validation and is not yet approved by accreditation bodies for single use in clinical scenarios. However, compared to HPV DNA-ISH, use of HPV RNA-ISH will reduce the number of patients incorrectly considered p16-positive/HPV-negative by approximately half. Therefore, the use of p16 IHC in combination with a second line ISH test, preferably RNA-ISH by RNAscope\textregistered on the basis of these results, should be considered. RNA-ISH by RNAscope is superior because, due to the uniqueness of the probe design, it has a very high signal to noise ratio which makes interpretation of positive vs negative cases unequivocal.\textsuperscript{12} This combination has been demonstrated to be sensitive, specific and easily interpreted. We have previously identified that p16-positive/HPV-negative patients as having distinctly poorer survival compared to true HPV-positive patients.\textsuperscript{17} This work clearly supports the
need for appropriate validation and integration of HPV RNA-ISH techniques such as the RNAscope® assay into the algorithm for determining HPV status in FFPE tissues from patients with OPSCC. It also shows the importance of identifying p16-positive/HPV-negative cases despite their low incidence within the oropharynx. The work presented in this study is the first to definitively compare the effectiveness of HPV molecular tests to p16 status in order to determine their benefit as second-line clinical tests.

**Acknowledgements:** This work received funding from the Medical Research Council (R1310CNR; DMcC and JJ), the Health and Social Care Research and Development Division of the Northern Ireland Public Health Agency (R4556CNR; DmC, JI, MMO), Cancer Research UK (R2111CNR; MST and JJ), the Wellcome Trust through the Wellcome-FDS Research Training Fellowship, the Faculty of Dental Surgery of the Royal College of Surgeons of England (WT093893MA; AS) and GlaxoSmithKline Ltd (TJ). The Northern Ireland OPSCC TMAs used in this research were received from the Northern Ireland Biobank, which has received funds from Health and Social Care Research and Development Division of the Public Health Agency in Northern Ireland and the Friends of the Cancer Centre. The Northern Ireland Cancer Registry who receives funding from the Northern Ireland Public Health Agency carried out collection of clinical data for the Northern Ireland OPSCC patients.

**References**


**Tables**

<table>
<thead>
<tr>
<th></th>
<th>Included (n=221)</th>
<th>Excluded (n=73)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-59</td>
<td>111 (50%)</td>
<td>34 (47%)</td>
<td>0.6848</td>
</tr>
<tr>
<td>60+</td>
<td>110 (50%)</td>
<td>39 (53%)</td>
<td></td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td>0.306</td>
</tr>
<tr>
<td>Male</td>
<td>164 (74%)</td>
<td>49 (67%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>57 (26%)</td>
<td>24 (33%)</td>
<td></td>
</tr>
<tr>
<td><strong>TNM7</strong></td>
<td></td>
<td></td>
<td>0.4971</td>
</tr>
<tr>
<td>I</td>
<td>19 (9%)</td>
<td>8 (11%)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>28 (13%)</td>
<td>14 (19%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>35 (16%)</td>
<td>12 (16%)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>130 (59%)</td>
<td>35 (48%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>9 (4%)</td>
<td>4 (5%)</td>
<td></td>
</tr>
<tr>
<td><strong>Smoker Status</strong></td>
<td></td>
<td></td>
<td>0.2951</td>
</tr>
<tr>
<td>Never or Previous</td>
<td>76 (34%)</td>
<td>25 (34%)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>91 (41%)</td>
<td>24 (33%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>54 (24%)</td>
<td>24 (33%)</td>
<td></td>
</tr>
<tr>
<td><strong>Alcohol History</strong></td>
<td></td>
<td></td>
<td>0.8839</td>
</tr>
<tr>
<td></td>
<td>p16-positive (n=90)</td>
<td>p16-negative (n=131)</td>
<td>p</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------</td>
<td>----------------------</td>
<td>------</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-59</td>
<td>56 (62%)</td>
<td>55 (42%)</td>
<td>0.0048</td>
</tr>
<tr>
<td>60 +</td>
<td>34 (38%)</td>
<td>76 (58%)</td>
<td>..</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>72 (80%)</td>
<td>92 (70%)</td>
<td>..</td>
</tr>
<tr>
<td>Female</td>
<td>18 (20%)</td>
<td>39 (30%)</td>
<td>..</td>
</tr>
<tr>
<td><strong>TNM7</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>1 (1%)</td>
<td>18 (14%)</td>
<td>..</td>
</tr>
<tr>
<td>II</td>
<td>6 (7%)</td>
<td>22 (17%)</td>
<td>..</td>
</tr>
<tr>
<td>III</td>
<td>14 (16%)</td>
<td>21 (16%)</td>
<td>..</td>
</tr>
<tr>
<td>IV</td>
<td>69 (77%)</td>
<td>61 (47%)</td>
<td>..</td>
</tr>
<tr>
<td>Missing</td>
<td>0 (0%)</td>
<td>9 (7%)</td>
<td>..</td>
</tr>
<tr>
<td><strong>Smoker Status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never or Previous</td>
<td>47 (52%)</td>
<td>29 (22%)</td>
<td>..</td>
</tr>
<tr>
<td>Current</td>
<td>22 (24%)</td>
<td>69 (53%)</td>
<td>..</td>
</tr>
<tr>
<td>Missing</td>
<td>21 (23%)</td>
<td>33 (25%)</td>
<td>..</td>
</tr>
</tbody>
</table>

Table 1: **Comparison of baseline characteristics between included and excluded study patients.** Data is presented as number of patients (%). Differences in patient characteristics between included and excluded study patients were compared using Fisher’s exact test for categorical variables.
Table 2: Baseline characteristics of study patients, according to p16 status. Data is presented as number of patients (%). Differences in patient characteristics according to p16 status were compared using Fisher's exact test for categorical variables.

<table>
<thead>
<tr>
<th>Alcohol History</th>
<th>..</th>
<th>..</th>
<th>0.8181</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>13 (14%)</td>
<td>21 (16%)</td>
<td>..</td>
</tr>
<tr>
<td>Yes</td>
<td>41 (46%)</td>
<td>63 (48%)</td>
<td>..</td>
</tr>
<tr>
<td>Missing</td>
<td>36 (40%)</td>
<td>47 (36%)</td>
<td>..</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Curative Intent with Surgery</th>
<th>..</th>
<th>..</th>
<th>0.0024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>60 (67%)</td>
<td>64 (49%)</td>
<td>..</td>
</tr>
<tr>
<td>No</td>
<td>25 (28%)</td>
<td>39 (30%)</td>
<td>..</td>
</tr>
<tr>
<td>No Treatment/Palliative</td>
<td>5 (6%)</td>
<td>28 (21%)</td>
<td>..</td>
</tr>
</tbody>
</table>

Figure Legends

Figure 1. STROBE diagram.
Figure 1 details the selection process used when identifying the untreated primary OPSCC patients and samples used in the current study.

Figure 2. Staining patterns demonstrated in patient samples by p16 IHC, HPV RNA and DNA ISH at x40 magnification.
Figure 2 contains the staining pattern observed in a patient with p16+/HPV RNA ISH+/HPV DNA ISH+ staining (A), a patient with p16+/HPV RNA ISH+/HPV DNA ISH- staining (B), a patient with p16+/HPV RNA ISH-/HPV DNA ISH- staining (C) and a patient with p16-/HPV RNA ISH-/HPV DNA ISH- staining (D).

Figure 3. Sensitivity and specificity of the HPV tests to p16 IHC.
Figure 3 contains a visual representation of HPV-positive cases by each test in relation to p16 positivity (A). Forest plots of computed sensitivity (B) and specificity (C) by each HPV test to p16-positive OPSCC. Time trend analysis of p16-/HPV+ (D) and p16+/HPV- (E) patients in relation to block year. Incidence before and after 2006 was assessed using logistic regression. Incidence was not assessed for DNA-ISH and RNA-ISH in D as no patients were found to be p16-/HPV+ using these two assays.

Figure 4. Kaplan-Meier estimates of five-year overall survival.

Figure 4 contains the Kaplan-Meier estimates of five-year overall survival for p16 IHC (A), HPV RNA-ISH (B), HPV DNA-ISH (C), HPV DNA-PCR (D), combined p16 IHC/HPV DNA-PCR (E), and combined p16 IHC/HPV RNA-ISH (F). Global differences in survival curves were compared through use of the log-rank test.
OPSCC patients reported in Northern Ireland (2000-2011) n=337

Patients excluded following clinical note review (n=43):
- Recurrence (n=22)
- Tumour site (n=12)
- Ex-regional (n=8)
- Rare histological subtype (n=1)

Patients included in the cohort and clinical data analysis n=294 (100%)

Patients with retrieved FFPE biopsy or surgical resection specimens suitable for TMA construction n=250 (85%)

Patients with HPV status reported by all 4 tests under investigation n=221 (75%)
4. A. **p16 IHC**
   - Survival (Years)
   - Fraction Survival
   - p16- n=131
   - p16+ n=90

4. C. **HPV DNA-ISH**
   - Survival (Years)
   - Fraction Survival
   - HPV- n=154
   - HPV+ n=67

4. E. **p16 IHC/HPV DNA-PCR**
   - Survival (Years)
   - Fraction Survival
   - p16- n=150
   - p16+/HPV+ n=71

4. B. **HPV RNA-ISH**
   - Survival (Years)
   - Fraction Survival
   - HPV- n=141
   - HPV+ n=80

4. D. **HPV DNA-PCR**
   - Survival (Years)
   - Fraction Survival
   - HPV- n=106
   - HPV+ n=114

4. F. **p16 IHC/HPV RNA-ISH**
   - Survival (Years)
   - Fraction Survival
   - p16-/HPV- n=131
   - p16+/HPV+ n=80
   - p16+/HPV- n=10